Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: PR Newswire
NEW YORK, April 24, 2020 /PRNewswire/ -- Voltron Therapeutics, Inc. announced today that it has selected the peptides required to complete the structure of HaloVax for development and progression into pre-clinical animal testing of the HaloVax Self-Assembling Vaccine (SAV). Voltron will take two different vaccines, with differing sets of targets into pre-clinical testing, in order to identify the best balance of immune responses for prevention of infection. This vaccine is designed to protect patients at risk of coronavirus (COVID-19) infection. Initiation of the first animal study for the vaccine candidates is expected to begin in May 2020.The vaccine candidates are built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which used adjuvants like alum. The second portion of the vaccine consists of peptides from the COVID-19 virus, which are bound at high affinity to the heat shock pro
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024PR Newswire
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsPR Newswire
HOTH
Sec Filings
- 4/22/24 - Form 424B3
- 4/22/24 - Form EFFECT
- 4/11/24 - Form S-1
- HOTH's page on the SEC website